Lv21
170 积分 2024-09-21 加入
Safety and efficacy of the new, oral, small-molecule, GLP-1 receptor agonists orforglipron and danuglipron for the treatment of type 2 diabetes and obesity: systematic review and meta-analysis of randomized controlled trials
6小时前
待确认
Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial
7小时前
已完结
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment
7小时前
已完结
Aldose reductase -mediated HUR ubiquitination enhances exosome release and hepatic fibrosis via ROS/PI3K/AKT pathway
3个月前
已完结
Efficacyandsafetyofdanuglipron(PF-06882961) inadults withobesity:Arandomized,placebo-controlled,dose-ranging phase2bstudy
5个月前
已完结
Global risk factors, epidemiology, and disease burden of type 2 diabetes
5个月前
已完结
Obesity and diabetes
10个月前
已完结
皖公网安备34019202002308
